Aloar een betere orale antistollingstherapie in de kliniek Een taak voor deskundigen

Pharmaceutisch Weekblad

Volumn 135, Issue 7, 2000, Pages 235-241

  Risselada, P M L A ^a   Van Beinema, Den Bemt M J ^a   Brouwers, J R B J ^a  

^a Apotheek Ziekenhuis de Tjongerschans   (Netherlands)

Author keywords

Anticoagulants; Computer assisted Hemorrhage; Dosage; Drug interactions; Drug therapy

Indexed keywords

EID: 33748591087     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993:153:1557-62.
2. Levine MM, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(4):276S-90S.
3. Ansell JE. Anticoagulation management as a risk factor for adverse events: grounds for improvement. J Thromb Thrombolys 1998:5:513-58.
4. Raj G, Kumar R, McKinney WP. Long-term oral anticoagulant therapy: update on indications, therapeutic ranges, and monitoring. Am J Med Sei 1994;307(2):128-32.
5. Ansell JE. The value of a specialized program for the management of oral anticoagulation. Hämostaseologie 1997;17:133-6.
6. Hafner J, De Moerloose P, Bounameaux H. Oral anticoagulation alone or in combination with aspirin: risks and benefits. Vasa 1996;25(1):1-12.
7. Kuijer PMM, Hütten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;!59:457-60.
8. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996:348:423-8.
9. Launbjerg J, Egeblad H, Heaf J, et al. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Int Med 1991 ;229:351 -5.
10. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995;26(8):1471-7.
11. Scott PJW. Anticoagulant drugs in the elderly: the risks usually outweigh the benefits. BMJ 1988;297:1261-3.
12. White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med 1996:156:1197-201.
13. Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a populationbased study in Rochester, Minnesota. Mayo Clin Proc 1995:70:725-33.
14. Aithal GP, Day CP, Kesteven PJL, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1998:353:717-9.
15. Schulman S, Granqvist S, Holmstrom M, et al. The durations of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336(6):393-9.
16. ShorrRI, Ray WA, DaughertyJR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-9.
17. Vanscoy GJ, Coax WC. Oral anticoagulantion: improving the riskbenefit ratio. J Fam Pract !995;41(3):261-7.
18. Davidson JF, Colvin BT, BarrowcliffeTW, et al. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990;43:177-83.
19. Ariyaratnam S, Thakkcr NS, Sloan P, et al. Potentiation of warfarin anticoagulant activity by miconazole oral gel. BMJ 1997:314:49.
20. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants; mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(4):231S-46S.
21. Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992;32:196-209.
22. Fiore LD. Anticoagulation: risks and benefits in atrial fibrillation. Geriatrics 1996;51(6):22-31.
23. Quinn Dl, Day RO. Drug interactions of clinical importance. An updated guide. Drug Saf 1995;12(6):393-452.
24. Stockley IH. Anticoagulant drug interactions. In: Stockley IH, red., Drug interactions. 4e ed. Nottingham: The Pharmaceutical Press, 1996:232-303.
25. De Smet PAGM, van Loenen AC, Offerhaus L, van der Does E, red. Medicatiebegeleiding. Utrecht: Bohn Stafleu van Loghum, 1990.
26. Wetenschappelijk Instituut Nederlandse Apothekers. Informatorium Medicamentorium 1999. 's-Gravenhage: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 1999:289.
27. Farmacotherapeutisch Kompas 1999. Amstelveen: Ziekenfondsraad, 1999:231-3.
28. Commentaren Medicatiebewaking Pharmacom Medicom 1998. Houten:Stichting Health Base, 1998:51, 116,209,223.
29. Repertorium 98/99. Utrecht: Nefarma ft Neprofarm, 1998:109-11.
30. Commissie Interacterende Medicatie Coumarines. Standaardafhandeling cumarine-ineracties. 's-Gravenhage: Wetenschappelijk Instituut Nederlandse Apothekers, 1999 äug.
31. Horikx A, Le Comte M. Standaard afhandeling cumarineinteracties op komst. Pharm Weekbl 1999;134(7):224.
32. Sun J, Chang MW. Initialization of warfarin dosages using computer modeling. Arch Phys Med Rehabil 1995:76;453-6.
33. Fitzmaurice DA, Hobbs FOR, Murray ET. Primary care anticoagulant clinic management using computerized decision support and near patient international normalized ratio (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 1998;15(2):144-6.
34. Dates A, Jackson PR, Austin ÇA, et al. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998:46:157-61.
35. Vadher B, Patterson DLH, Leaning M. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. BMJ 1997;314:1252-6.
36. Galloway MJ, Foggin JJ, Dixon S. Introduction of computer assisted control of oral anticoagulation in general practise. J Clin Pathol 1995:48:1144-6.
37. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998:352:1505-9.
38. Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management. J Thromb Thrombolys 1996;3:37783.
39. Fitzmaurice DA, Hobbs FOR, Delaney BC, et al. Review of computerized decision support systems for oral anticoagulation management. Br J Haematol 1998;102:907-9.
40. Fitzmaurice DA, Hobbs FOR, Murray ET, et al. Evaluation of computerized decision support for oral anticoagulation management based in primary care. BrJ Gen Pract 1996:46:533-5.
41. Yates P, Stear M. A mainframe interfacing computer management system for the control of oral anticoagulant therapy. Clin Lab Haemal 1992;14:245-50.
42. Preston FE. Quality control and oral anticoagulation. Thromb Haemost 1995;74(1):515-20.
43. Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993:46:299-303.
44. White RH, Hong R, Venook AP, et al. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J Gen Intern Med 1987:2:141-8.
45. Walker ID, Machin S, Baglin TP, et al. Guidelines on oral anticoagulation. 3rd ed. BrJ Haematol 1998:101:374-87.
46. Piersma-Wichers G. Ervaringen metTDAS bij de trombo'sedienst Groningen.Tromnibus 1995;23(3):39-41. X
47. Peters RHM, Poot J. TROMIS: automatiseringssysteem voor \ trombosediensten.Tromnibus 1995;23(3):41-3. \
48. Harrison L, Jonhston M, Massicottc MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126(2):l33-6.
49. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Eng J Med 1995:332:993-97.